治疗药物监测在系统性红斑狼疮治疗中的研究现状
|
摘要
系统性红斑狼疮(SLE)是一种因免疫调节功能紊乱、出现多种自身抗体、进而引起全身多系统损害的自身免疫病。硫酸羟氯喹和免疫抑制药(霉酚酸酯、钙调磷酸酶抑制药)在SLE患者治疗中占据重要地位。本文对目前关于SLE患者中的治疗药物监测(TDM)研究(羟氯喹、霉酚酸酯、钙调磷酸酶抑制药)进行了综述。
Systemic lupus erythematosus( SLE) is a multisystem autoimmune disorder, characterized by the production of a wide range of autoantibodies. Currently,hydroxychloroquine and immunosuppressive agents( mycophenolate mofetil,calcineurin inhibition) have become important components for the treatment of SLE. In this review,we provide a detailed overview of the recent developments of therapeutic drug monitoring( TDM) in the management of SLE.
Systemic lupus erythematosus( SLE) is a multisystem autoimmune disorder, characterized by the production of a wide range of autoantibodies. Currently,hydroxychloroquine and immunosuppressive agents( mycophenolate mofetil,calcineurin inhibition) have become important components for the treatment of SLE. In this review,we provide a detailed overview of the recent developments of therapeutic drug monitoring( TDM) in the management of SLE.
引文
[1]BARNETT R.Systemic lupus erythematosus[J].Lancet,2016,387(10029):1711.
[2]ZHANG Y,ZHANG R.Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs[J].Drug Test Anal,2018,10(1):81-94.
[3]RAINSFORD K D,PARKE A L,CLIFFORD-RASHOTTE M,et al.Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus,rheumatoid arthritis and related diseases[J].Inflammopharmacology,2015,23(5):231-269.
[4]MOK C C,PENN H J,CHAN K L,et al.Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus:Alongitudinal cohort analysis[J].Arthritis Care Res,2016,68(9):1295-1302.
[5]FRANCèS C,COSNES A,DUHAUT P,et al.Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus:a French multicenter prospective study[J].Arch Dermatol,2012,148(4):479-484.
[6]COSTEDOAT-CHALUMEAU N,AMOURA Z,HULOT J S,et al.Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus[J].Arthritis Rheum,2006,54(10):3284-3290.
[7]司慧敏,王红,张华勇,等.系统性红斑狼疮患者羟氯喹血药浓度及安全性研究[J].中华风湿病学杂志,2015,19(10):678-681.
[8]COSTEDOAT-CHALUMEAU N,GALICIER L,AUMATRE O,et al.Hydroxychloroquine in systemic lupus erythematosus:results of a French multicentre controlled trial(PLUS Study)[J].Ann Rheum Dis,2013,72(11):1786-1792.
[9]JALLOULI M,FRANCS C,PIETTE J C,et al.Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus:a case-control study[J].JAMA Dermatol,2013,149(8):935-940.
[10]JALLOULI M,GALICIER L,ZAHR N.Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus[J].Arthritis Rheumatol,2015,67(8):2176-2184.
[11]KIANG T K L,ENSOM M H H.Population pharmacokinetics of mycophenolic acid:An update[J].Clin Pharmacokinet,2018,7(5):547-558.
[12]SHAW L M,KORECKA M,VENKATARAMANAN R,et al.Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies[J].Am J Transplant,2003,3(5):534-542.
[13]MOK C C.Mycophenolate mofetil for lupus nephritis:an update[J].Expert Rev Clin Immunol,2015,11(12):1353-1364.
[14]LERTDUMRONGLUK P,SOMPARN P,KITTANAMONGKOL-CHAI W.Pharmacokinetics of mycophenolic acid in severe lupus nephritis[J].Kidney Int,2010,78(4):389-395.
[15]ZAHR N,ARNAUD L,MARQUET P,et al.Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil[J].Arthritis Rheum,2010,62(7):2047-2054.
[16]ZABOTTI A,BARALDO M,QUARTUCCIO L,et al.Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring[J].Clin Rheumatol,2015,34(1):171-174.
[17]NEUMANN I,FUHRMANN H,FANG I F,et al.Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil[J].Nephrol Dial Transplant,2008,23(11):3514-3520.
[18]DJABAROUTI S,BREILH D,DUFFAU P,et al.Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares:an observational cohort study[J].Arthritis Res Ther,2010,12(6):217.
[19]SHARMA R K,PARAMESWARAN S.Calmodulin-binding proteins:A journey of 40 years[J].Cell Calcium,2018,75(5):89-100.
[20]MOK C C.Calcineurin inhibitors in systemic lupus erythematosus[J].Best Pract Res Clin Rheumatol,2017,31(3):429-438.
[21]MOK C C,YING K Y,YIM C W,et al.Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis:a randomised controlled trial and long-term follow-up[J].Ann Rheum Dis,2016,75(1):30-36.
[22]LI X,REN H,ZHANG Q,et al.Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis[J].Nephrol Dial Transplant,2012,27(4):1467-1472.
[23]LIU Z,ZHANG H,LIU Z,et al.Multitarget therapy for induction treatment of lupus nephritis:a randomized trial[J].Ann Intern Med,2015,162(1):18-26.
[24]VANHOVE T,ANNAERT P,KUYPERS D R.Clinical determinants of calcineurin inhibitor disposition:a mechanistic review[J].Drug Metab Rev,2016,48(1):88-112.
[25]SCALEA J R,LEVI S T,ALLY W,et al.Tacrolimus for the prevention and treatment of rejection of solid organ transplants[J].Expert Rev Clin Immunol,2016,12(3):333-342.
[26]WALLEMACQ P,ARMSTRONG V W,BRUNET M,et al.Opportunities to optimize tacrolimus therapy in solid organ transplantation:report of the European consensus conference[J].Ther Drug Monit,2009,31(2):139-152.
[27]MOK C C.Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus[J].Expert Rev Clin Immunol,2017,13(1):35-41.
[28]MOK C C.Pro:The use of calcineurin inhibitors in the treatment of lupus nephritis[J].Nephrol Dial Transplant,2016,31(10):1561-1566.
[29]费允云,吴庆军,张文,等.他克莫司治疗难治性狼疮肾炎的疗效和安全性[J].中华风湿病学杂志,2012,16(1):9-12.
[2]ZHANG Y,ZHANG R.Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs[J].Drug Test Anal,2018,10(1):81-94.
[3]RAINSFORD K D,PARKE A L,CLIFFORD-RASHOTTE M,et al.Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus,rheumatoid arthritis and related diseases[J].Inflammopharmacology,2015,23(5):231-269.
[4]MOK C C,PENN H J,CHAN K L,et al.Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus:Alongitudinal cohort analysis[J].Arthritis Care Res,2016,68(9):1295-1302.
[5]FRANCèS C,COSNES A,DUHAUT P,et al.Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus:a French multicenter prospective study[J].Arch Dermatol,2012,148(4):479-484.
[6]COSTEDOAT-CHALUMEAU N,AMOURA Z,HULOT J S,et al.Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus[J].Arthritis Rheum,2006,54(10):3284-3290.
[7]司慧敏,王红,张华勇,等.系统性红斑狼疮患者羟氯喹血药浓度及安全性研究[J].中华风湿病学杂志,2015,19(10):678-681.
[8]COSTEDOAT-CHALUMEAU N,GALICIER L,AUMATRE O,et al.Hydroxychloroquine in systemic lupus erythematosus:results of a French multicentre controlled trial(PLUS Study)[J].Ann Rheum Dis,2013,72(11):1786-1792.
[9]JALLOULI M,FRANCS C,PIETTE J C,et al.Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus:a case-control study[J].JAMA Dermatol,2013,149(8):935-940.
[10]JALLOULI M,GALICIER L,ZAHR N.Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus[J].Arthritis Rheumatol,2015,67(8):2176-2184.
[11]KIANG T K L,ENSOM M H H.Population pharmacokinetics of mycophenolic acid:An update[J].Clin Pharmacokinet,2018,7(5):547-558.
[12]SHAW L M,KORECKA M,VENKATARAMANAN R,et al.Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies[J].Am J Transplant,2003,3(5):534-542.
[13]MOK C C.Mycophenolate mofetil for lupus nephritis:an update[J].Expert Rev Clin Immunol,2015,11(12):1353-1364.
[14]LERTDUMRONGLUK P,SOMPARN P,KITTANAMONGKOL-CHAI W.Pharmacokinetics of mycophenolic acid in severe lupus nephritis[J].Kidney Int,2010,78(4):389-395.
[15]ZAHR N,ARNAUD L,MARQUET P,et al.Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil[J].Arthritis Rheum,2010,62(7):2047-2054.
[16]ZABOTTI A,BARALDO M,QUARTUCCIO L,et al.Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring[J].Clin Rheumatol,2015,34(1):171-174.
[17]NEUMANN I,FUHRMANN H,FANG I F,et al.Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil[J].Nephrol Dial Transplant,2008,23(11):3514-3520.
[18]DJABAROUTI S,BREILH D,DUFFAU P,et al.Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares:an observational cohort study[J].Arthritis Res Ther,2010,12(6):217.
[19]SHARMA R K,PARAMESWARAN S.Calmodulin-binding proteins:A journey of 40 years[J].Cell Calcium,2018,75(5):89-100.
[20]MOK C C.Calcineurin inhibitors in systemic lupus erythematosus[J].Best Pract Res Clin Rheumatol,2017,31(3):429-438.
[21]MOK C C,YING K Y,YIM C W,et al.Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis:a randomised controlled trial and long-term follow-up[J].Ann Rheum Dis,2016,75(1):30-36.
[22]LI X,REN H,ZHANG Q,et al.Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis[J].Nephrol Dial Transplant,2012,27(4):1467-1472.
[23]LIU Z,ZHANG H,LIU Z,et al.Multitarget therapy for induction treatment of lupus nephritis:a randomized trial[J].Ann Intern Med,2015,162(1):18-26.
[24]VANHOVE T,ANNAERT P,KUYPERS D R.Clinical determinants of calcineurin inhibitor disposition:a mechanistic review[J].Drug Metab Rev,2016,48(1):88-112.
[25]SCALEA J R,LEVI S T,ALLY W,et al.Tacrolimus for the prevention and treatment of rejection of solid organ transplants[J].Expert Rev Clin Immunol,2016,12(3):333-342.
[26]WALLEMACQ P,ARMSTRONG V W,BRUNET M,et al.Opportunities to optimize tacrolimus therapy in solid organ transplantation:report of the European consensus conference[J].Ther Drug Monit,2009,31(2):139-152.
[27]MOK C C.Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus[J].Expert Rev Clin Immunol,2017,13(1):35-41.
[28]MOK C C.Pro:The use of calcineurin inhibitors in the treatment of lupus nephritis[J].Nephrol Dial Transplant,2016,31(10):1561-1566.
[29]费允云,吴庆军,张文,等.他克莫司治疗难治性狼疮肾炎的疗效和安全性[J].中华风湿病学杂志,2012,16(1):9-12.